Skip to main content
×

GE.com has been updated to serve our three go-forward companies.

Please visit these standalone sites for more information

GE Aerospace | GE Vernova | GE HealthCare 

Press Release

GE Healthcare Expands Portfolio of ecomagination Products

February 02, 2010
Press Release

FDA ADVISORY COMMITTEE RECOMMENDS DaTSCAN™ (Ioflupane I 123 Injection)

August 11, 2009

PRINCETON, NJ--GE Healthcare announced today that the Peripheral and Central Nervous System Drugs advisory committee of the U.S. Food and Drug Administration (FDA) has voted to recommend DaTSCAN (Ioflupane I 123 Injection) to the FDA. The panel determined DaTSCAN has a favorable risk to benefit profile, voting 11 to two with one abstention.


business unit
tags
Press Release

GE Healthcare's Senographe DS Ranked as Top Digital Mammography Product in 2009 "Best in KLAS" Report

August 07, 2009

Ranking determined by medical equipment performance data collected from healthcare provider organization

WAUKESHA, WI - The Senographe® DS digital mammography system has been ranked as the #1 digital mammography system in the 2009 Top 20 Best in KLAS® Awards for Medical Equipment in the Digital Mammography category. The announcement was made by GE Healthcare, a division of General Electric Corp. (NYSE: GE).


business unit
tags
Press Release

GE Healthcare Debuts Dedicated Molecular Imaging Business at 2009 Society of Nuclear Medicine Conference

June 12, 2009

With newly dedicated business segment, GE Healthcare announces vision for Molecular Imaging industry; highlights comprehensive solution portfolio.

WAUKESHA, Wis.--12 June 2009-- GE Healthcare will present a new vision for molecular imaging, "Understanding disease. From the beginning," reinforced by its innovative platform of imaging agents and imaging systems at the 56th annual meeting of the Society of Nuclear Medicine, June 13- 17, in Toronto, Canada.


business unit
tags
Press Release

GE Healthcare's Application For DaTSCAN™ (Ioflupane I123 Injection) Accepted By The FDA For Priority Review

June 02, 2009

PRINCETON, NJ, JUNE 2, 2008--- GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 injection) for priority review.


business unit
tags
Press Release

GE Healthcare Applauds CMS for Supporting National FDG-PET Coverage Decision

April 07, 2009

Expanded Medicare coverage of PET scans improves access for patients to needed cancer diagnosis tool


WAUKESHA, WIS. -- APRIL 07, 2009 -- GE Healthcare, a global leader in healthcare technology, supports the recent national coverage determination (NCD) from the Centers for Medicare and Medicaid Services (CMS), expanding coverage for initial testing with positron emission tomography (PET) for Medicare beneficiaries who are diagnosed with and treated for most solid tumor cancers.


business unit
tags
Press Release

GE Healthcare to Include Urgent Public Health Alerts in Electronic Medical Records

April 05, 2009

Pilot Program Aims to Alert Physicians to Timely, Relevant Health Information to Help Improve Patient Outcomes

HIMSS 2009 Annual ConferenceBooth 3619


business unit
tags
Press Release

GE Healthcare Announces Data From Phase III Study of AdreView in Heart Failure Patients

March 31, 2009

ORLANDO, FL--GE Healthcare, a unit of General Electric Company (NYSE: GE), presented results from the ADMIRE-HF study at the American College of Cardiology's 58th Annual Scientific Session in Orlando, Florida today. The study involved a nuclear imaging test utilizing the imaging agent AdreView™ (Iobenguane I 123 injection) in heart failure patients who are at a higher risk for cardiac death, disease progression, or cardiac arrhythmias.

ADMIRE-HF Data


business unit
tags
Press Release

GE Healthcare Delivers "Clinically Relevant Solutions" to ACC09

March 30, 2009

Company Announces New Products, Collaborations and Initiatives at Orlando Expo

ACC.09 Annual Scientific Session Exposition

ORLANDO, Fla.--(BUSINESS WIRE)--GE Healthcare is dedicated to delivering tomorrow's healthcare solutions today. New products, collaborations and ideas are at the heart of the company's product lineup at the American College of Cardiology (ACC) conference, in Orlando through Tuesday, March 31.


business unit
tags
Press Release

Pascale Witz Named President and CEO of GE Healthcare Medical Diagnostics

March 19, 2009

Princeton, NJ--- John Dineen, president and CEO of GE Healthcare, has appointed Pascale Witz to the position of president and CEO, GE Healthcare, Medical Diagnostics. In her most recent assignment, Ms. Witz led GE Healthcare's Healthcare Systems Interventional global business, which researches and develops innovative medical technologies to help physicians diagnose and treat disease earlier, faster and more accurately.


business unit
tags
Subscribe to Medical Diagnostics